Q4 2025 net product revenue for ZORYVE® (roflumilast) was $127.5 million, an 84% increase compared to Q4 2024, and a 29% increase compared to Q3 2025Full year 2025 net product ...
Richard R. Redfern, M.S., C.P.G. No. 10717, an independent Consulting Geologist for Fairchild and a "qualified person" as defined in NI 43-101, has reviewed and approved the scientific and technical ...
Some Roman Catholic parishes are reporting rising membership for the first time in years, and it appears a new generation of worshippers is starting to fill the pews.
Royalty Pharma’s valuation remains attractive, supported by sector momentum and sustained capital returns. Click here to know ...
This contribution is part of the special series of Inaugural Articles by members of the National Academy of Sciences elected in 2021. Mitochondria originated from ancestral bacteria and they still ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results